FFR 0 1 2002

SEQUENCE LISTING

<110> CELT PHARMACEUTICALS, INC.

TWARDZIK, Daniel

FELKER, Thomas PERNET, Andre

PASKELL, Stefan

<120> TGF-alpha POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

<130> STEM1110-3

<140> US 09/932,172

<141> 2001-08-17

<150> US 09/641,587

<151> 2000-08-17

<150> US 09/492,935

<15.5 2000-01-27

<150: US 09/378/5

<151> 1999-(3-1)

<160> 7

<170> Patent

Э1. .

<210> 1

<211> 50

<212> PRT

<213> Homo gapi as

<400> 1

Val Val Ser Mac Phe Asn Asp Tys Pro Asp Ser His Thr Gln Phe Cys

1 10 15

Phe His Gly Thr Cys Arg This Lou Val Gln Glu Asp Lys Pro Ala Cys 20 25 30

Val Cys His Ser Gly 15th Val Cly Ala Arg Cys Glu His Ala Asp Leu 35 40 45

Leu Ala 50

<210> 2

<211> 50

<212> PRT

<213> Rattus norvegicus

<400> 2

Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr Gln Tyr Cys
1 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Glu Lys Pro Ala Cys

Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu

35 40 45

```
Asp Ala
   50
<210> 3
<211>
      57
<212>
      PRT
<213> Artificial sequence
<220>
<223> A modified human TGF-alpha sequence
<400> 3
Ser Leu Ser Leu Pro Ala Met Val Val Ser His Phe Asn Asp Cys Pro
Asp Ser His Thr Gln Phe Cys Phe His Gly Thr Cys Arg Phe Leu Val
Gln Glu Asp Lys Fro Ala Cys Val Cys His Ser Gly Tyr Val Gly Ala
Arg Cys Glu His Ala Asp Lou Leu Ala
<210> 4
<211> 11
<212> PRT
<213> Artificial sequence
<220>
<223> Artificial peptide sequence
<220>
<221> VARIANT
<222>
      (1)..(10)
<223> Xaa at residue 1, 5, 7 to 9 is independently V, G or A; Xaa at
       residue 6 is Y or F; and Xaa at residue 10 is R or K
<400> 4
Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Cys
<210>
       5
       7
<211>
<212> PRT
<213> Artificial sequence
<220>
<223> Artificial peptide sequence
<220>
<221> VARIANT
<222>
      (1)..(7)
```

<223> Xaa at residue 1 and 4 is E or D; Xaa at residue 3 and 7 is V, G,

or A; Xaa at residue 5 is L or I; and Xaa at residue 6 is D or E

٠. .٠. .٠. ..

```
<400> 5
Xaa His Xaa Xaa Xaa Xaa
                5
<210> 6
<211> 18
<212> PRT
<213> Artificial sequence
<220>
<223> Artificial peptide sequence
<220>
<221> VARIANT
<222>
      (1)..(18)
<223> Xaa at residue 1, 5, 7-9, 14, 18 is indep. V, G, or A; Xaa at
       residue 6 is Y or F; Xaa at residue 10 is R or K; Xaa at residue 12,
        15 is indep. E or D; Xaa at residue 16 is L or I; Xaa at residue
        17 is D or E
<400> 6
Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Cys Xaa His Xaa Xaa Xaa
Xaa Xaa
<210> 7
<211> 7
<212> PRT
<213> Artificial sequence
<220>
<223> Artificial peptide sequence
<220>
<221> VARIANT
<222> (1)..(7)
<223> Xaa at residue 1 and 2 is indep. V, G, and A; Xaa at residue 7 is
       K or R
<400> 7
Xaa Xaa Ser His Phe Gln Xaa
```